208 related articles for article (PubMed ID: 33165815)
1. Activities and polymorphisms of MMP-2 and MMP-9, smoking, diabetes and risk of prostate cancer.
Kiani A; Kamankesh M; Vaisi-Raygani A; Moradi MR; Tanhapour M; Rahimi Z; Elahi-Rad S; Bahrehmand F; Aliyari M; Aghaz F; Mozafari H; Rezvani N; Haghnazari L; Pourmotabbed T
Mol Biol Rep; 2020 Dec; 47(12):9373-9383. PubMed ID: 33165815
[TBL] [Abstract][Full Text] [Related]
2. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort.
Srivastava P; Kapoor R; Mittal RD
Gene; 2013 Nov; 530(2):273-7. PubMed ID: 23872201
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
[TBL] [Abstract][Full Text] [Related]
4. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
5. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
7. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
9. Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population.
Elahirad S; Elieh Ali Komi D; Kiani A; Mohammadi-Noori E; Vaisi-Raygani A; Mozafari H; Bahrehmand F; Saidi M; Toupchi-Khosroshahi V; Salehi N
Cardiovasc Toxicol; 2022 Feb; 22(2):118-129. PubMed ID: 34731407
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
11. Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration.
Oszajca K; Szemraj M; Szemraj J; Jurowski P
Ophthalmic Genet; 2018 Dec; 39(6):684-698. PubMed ID: 30289322
[TBL] [Abstract][Full Text] [Related]
12. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
[TBL] [Abstract][Full Text] [Related]
13. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
[TBL] [Abstract][Full Text] [Related]
15. Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Variants, Their Serum Levels, and Activities with Aortic Valve Calcification (AVC) in a Population from Western Iran.
Heidari Moghadam R; Babajani F; Karami A; Elieh-Ali-Komi D; Hoseini F; Salehi N; Elahirad S; Mohammadi-Noori E; Mohammadi H; Kiani A
Genet Test Mol Biomarkers; 2024 Jun; 28(6):223-232. PubMed ID: 38708584
[No Abstract] [Full Text] [Related]
16. Diabetes may affect the expression of matrix metalloproteinases and their inhibitors more than smoking in chronic periodontitis.
Bastos MF; Tucci MA; de Siqueira A; de Faveri M; Figueiredo LC; Vallim PC; Duarte PM
J Periodontal Res; 2017 Apr; 52(2):292-299. PubMed ID: 27363729
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
18. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
Marson BP; Lacchini R; Belo V; Dickel S; da Costa BP; Poli de Figueiredo CE; Tanus-Santos JE
Am J Nephrol; 2012; 35(3):209-15. PubMed ID: 22302011
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]